Regel Therapeutics - About the company
Regel Therapeutics is a funded company based in Cambridge (United States), founded in 2019 by Jordane Dimidschstein and Navneet Matharu. It operates as a Developer of targeted gene therapies for genetic diseases. Regel Therapeutics has raised an undisclosed amount in funding. The company has 2829 active competitors, including 979 funded and 701 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics.
Company Details
Developer of targeted gene therapies for genetic diseases. The company utilizes a deactivated Cas system (dCas) which targets the epigenome without editing or damaging the DNA for the treatment of genetic disorders that affect the central nervous system, skeletal muscles and the cardiovascular system.
- Website
- regeltherapeutics.com
- Email ID
- *****@regeltherapeutics.com
Key Metrics
Founded Year
2019
Location
Cambridge, United States
Stage
Funding Raised
Latest Funding Round
Investors
Ranked
1166th among 2829 active competitors
Employee Count
6 as on Jul 01, 2024
Similar Companies
Sign up to download Regel Therapeutics' company profile
Regel Therapeutics's funding and investors
Regel Therapeutics has raised funding over 1 round. Regel Therapeutics has 1 institutional investor.
Here is the list of recent funding rounds of Regel Therapeutics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 29, 2023 | 9282036 | Grant (prize money) | 8988387 | 3760870 | 7626361 | 6766635 |
Access funding benchmarks and valuations. Sign up today!View details of Regel Therapeutics's funding rounds and investors
Regel Therapeutics' founders and board of directors
Founder? Claim ProfileThe founders of Regel Therapeutics are Jordane Dimidschstein and Navneet Matharu. Megan McGil is the CEO of Regel Therapeutics.
Here are the details of Regel Therapeutics' key team members:
- Jordane Dimidschstein: Founder & Chief Operating Officer of Regel Therapeutics.
- Navneet Matharu: Founder/CSO of Regel Therapeutics.
- Megan McGil: CEO of Regel Therapeutics.
View details of Regel Therapeutics's Founder profiles and Board Members
Regel Therapeutics' employee count trend
Regel Therapeutics has 6 employees as of Jul 24. Here is Regel Therapeutics's employee count trend over the years:
Uncover Regel Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Regel Therapeutics's Competitors and alternates
Top competitors of Regel Therapeutics include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Here is the list of Top 10 competitors of Regel Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of genetically engineered cell therapies for multiple disorders | $821M | 75/100 | |
3rd | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 74/100 | |
4th | Juno Therapeutics 2013, Seattle (United States), Acquired | Global biopharmaceutical company discovering, developing, and delivering innovative medicines | $317M | 74/100 | |
5th | Blueprint Medicines 2008, Cambridge (United States), Acquired | Developer of selective kinase inhibitors for patients with genomically defined cancers | $115M | 73/100 | |
6th | _1548135965397.png?devicePixelRatio=2&height=30&width=30){kind=logo} Kronos Bio 2017, San Mateo (United States), Acquired | Developer of small molecule based therapeutics for cancer treatment | $271M | 72/100 | |
7th | Pacira 2006, Parsippany Troy Hills (United States), Public | Developer of injectable non-opioid products for post-surgical pain control | $85M | 72/100 | |
8th | MacroGenics 2000, Rockville (United States), Public | Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease | $126M | 72/100 | |
9th |  Harbour BioMed 2016, Shanghai (China), Public | Developer of antibody therapeutics in immunology and oncology disease | $313M | 71/100 | |
10th |  iTeos Therapeutics 2011, Cambridge (United States), Acquired | Developer of immunotherapy for treating cancer | $204M | 70/100 | |
1166th |  Regel Therapeutics 2019, Cambridge (United States), Funding Raised | Developer of targeted gene therapies for genetic diseases | - | 37/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Regel Therapeutics's competitors? Click here to see the top ones
Regel Therapeutics's Investments and acquisitions
Regel Therapeutics has made no investments or acquisitions yet.
News related to Regel Therapeutics
Media has covered Regel Therapeutics for 1 event in last 1 year, It was about partnerships.
•
CRISPRa Method Reduces Seizures in Rare Genetic ConditionTechnology Networks•Sep 19, 2025•Regel Therapeutics, UCSF
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Regel Therapeutics
Explore our recently published companies
- Fast Dial - 2008 founded, Unfunded company
- Rage Communications - Sittingbourne based, 2013 founded, Unfunded company
- Employee Productivity Solutions - Lancaster based, 2012 founded, Unfunded company
- Iempresa Marketing - Madrid based, 1999 founded, Unfunded company
- iEduex | Colegios en el Extranjero - Madrid based, 2012 founded, Unfunded company
- Poley Creative - Portland based, 2019 founded, Unfunded company
